

# Valeant Pharmaceuticals Announces 2015 Annual Meeting Results

May 19, 2015

LAVAL, Quebec, May 19, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of eleven directors nominated at its 2015 annual meeting of shareholders today. The detailed results of the vote for the election of directors are set out below:

Name	For	Withheld	Broker Non-Votes
Ronald H. Farmer	259,517,209	2,064,596	12,938,661
Colleen A. Goggins	260,564,263	1,017,542	12,938,661
Robert A. Ingram	258,725,145	2,856,660	12,938,661
Anders Lönner	259,632,031	1,949,774	12,938,661
Theo Melas-Kyriazi	260,811,015	770,790	12,938,661
J. Michael Pearson	255,809,687	5,772,118	12,938,661
Robert N. Power	258,849,981	2,731,824	12,938,661
Norma A. Provencio	260,777,276	804,529	12,938,661
Howard B. Schiller	250,437,448	11,144,357	12,938,661
Katharine B. Stevenson	260,656,695	925,110	12,938,661
Jeffrey W. Ubben	260,166,082	1,415,723	12,938,661

At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation as disclosed in the proxy statement and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2016 annual meeting of shareholders.



The final vote tabulation on all matters voted on at today's meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site,

[www.valeant.com](http://www.valeant.com)

## About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant can be found at

[www.valeant.com](http://www.valeant.com)

## Contact Information:

Laurie W. Little

949-461-6002

[laurie.little@valeant.com](mailto:laurie.little@valeant.com)

To view the original version on PR Newswire, visit:

<http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-announces-2015-annual-meeting-results-300085929.html>

SOURCE Valeant Pharmaceuticals International, Inc.



## Investor Inquiries

[ir@bauschhealth.com](mailto:ir@bauschhealth.com)

877-281-6642

514-856-3855 (Canada)

## Media inquiries

[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com)

908-569-3692

LEGAL NOTICE

PRIVACY POLICY

EMAIL ALERTS

EMAIL PAGE

RSS FEED

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.

©2025 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION